New Canine Ear Treatment Combines Three Powerful Agents In Once-a-day Therapy

A new once-a-day treatment for otitis externa (inflammation of the outer ear and ear canal) in dogs is now available from Intervet/Schering-Plough Animal Health, a leader in treating canine ear disease. POSATEX™ (1% Orbifloxacin, 0.1% Mometasone Furoate Monohydrate and 0.1% Posaconazole, Otic Suspension), an effective antibacterial, anti-inflammatory and antifungal medication, is the next generation treatment for severe otitis externa in dogs. The seven-day treatment is designed to make compliance easier and bring fast relief to dogs suffering from this painful condition. Allan Weingarten, Director, Pharmaceutical Research, and POSATEX R&D Project Leader, said, “As every dog owner knows, this is a ‘nightmare’ disease. As experts in otic products, we feel a special responsibility to keep improving medications and continuing to make the course of treatment more effective, quicker and easier for both dogs and their caregivers.” The novel triazole antifungal posaconazole, new to animal health, is the latest example of innovation in this product area. POSATEX Otic Suspension, available in 7.5, 15 and 30g plastic bottles, is indicated for the treatment of otitis externa associated with susceptible strains of yeast (Malassezia pachydermatis) and bacteria (coagulase positive staphylococci, Pseudomonas aeruginosa and Enterococcus faecalis). Posaconazole, the newest element in the three-in-one combination, has been shown to be particularly effective against Malassezia pachydermatis and more potent than other veterinary antifungals. Mometasone furoate monohydrate is a potent and safe anti-inflammatory and Orbifloxacin is a broad-spectrum antibiotic with proven efficacy against bacteria. POSATEX Otic Suspension is contraindicated in dogs with known or suspected hypersensitivity to quinolones, mometasone furoate monohydrate or posaconazole. It should not be used in dogs with known tympanic membrane (ear drum) perforation. The safe use in dogs used for breeding purposes, during pregnancy or in lactating dogs has not been evaluated. The Product Label contains further information, including dose rate and complete directions and warnings. “Together with our expertise as a market leader, we wish to offer to our customers a comprehensive line of treatment for otitis externa in dogs”, said Nicolas Renard, Global Marketing Director for Companion Animal Pharmaceuticals. “This latest addition to our otic line will help us capitalize on both technical and commercial advantages with the objective of answering our customer requirements.” POSATEX Otic Suspension is the newest innovation from Intervet/Schering-Plough Animal Health. MOMETAMAX® (Gentamicin Sulfate, USP, Mometasone Furoate Monohydrate and Clotrimazole, USP Otic Suspension), containing a powerful once-a-day corticosteroid, was introduced in 2005, building on the success of earlier innovations, including OTOMAX® (Gentamicin Sulfate, USP Betamethasone Valerate, USP and Clotrimazole, USP Ointment). POSATEX™, MOMETAMAX® and OTOMAX® are the property of Intervet/Schering-Plough Animal Health and are protected by copyrights, trademark and other intellectual property laws.

More from

• IVC Evidensia assembles expert team to run new £10m referral hospital
• Home delivery service can increase pet health plan sign-ups by 25%
• Research reveals vital clues to help fight anthelmintic resistance
• Lifetime Achievement Award recognises Harrogate vet’s dedication to improving the health and welfare of rabbits
• Bake sale at Leicestershire vet practice for good cause